Clinical Study
Predictive and Prognostic Factors in Definition of Risk Groups in Endometrial Carcinoma
Table 6
Multivariate Cox proportional regression analyses of prognostic factors.
| Factor | Risk ratio | 95% CI | P value |
| Overall survival rate | | | | Age (>60 years) | 2.951 | 2.467–3.531 | <0.00001 | FIGO stage (III-IV versus I-II) | 2.489 | 2.169–2.855 | <0.00001 | Histology* | 1.569 | 1.340–1.836 | <0.00001 | FIGO grade (3 versus 1-2) | 1.814 | 1.590–2.069 | <0.00001 | Nuclear grade (3 versus 1-2) | 1.558 | 1.286–1.888 | <0.00001 | DNA ploidy** | 1.456 | 1.215–1.744 | <0.0001 | Myometrial infiltration*** | 1.322 | 1.164–1.501 | <0.0001 | P53 expression**** | 0.955 | 0.715–1.276 | 0.755 |
| Cancer-specific survival rate | | | | Age (>60 years) | 1.925 | 1.509–2.456 | <0.00001 | FIGO stage (III-IV versus I-II) | 4.205 | 3.542–4.993 | <0.00001 | Histology* | 1.717 | 1.410–2.090 | <0.00001 | FIGO grade (3 versus 1-2) | 2.524 | 2.099–3.035 | <0.00001 | Nuclear grade (3 versus 1-2) | 1.635 | 1.279–2.090 | <0.0001 | DNA ploidy** | 1.591 | 1.267–1.999 | <0.0001 | Myometrial infiltration*** | 1.292 | 1.069–1.561 | 0.008 | P53 expression**** | 1.089 | 0.747–1.587 | 0.657 |
|
|
*Nonendometrioid versus endometrioid. **Nondiploid versus diploid. ***>50% versus <50%. ****Positive (>30% staining) versus negative (<30% staining).
|